Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Leukemia 28Prostatic Neoplasms 21Burkitt Lymphoma 17Leukemia, Biphenotypic, Acute 15Lymphoma 13Leukemia, Myeloid, Acute 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Large B-Cell, Diffuse 6Recurrence 5Lymphoma, Non-Hodgkin 5Myelodysplastic Syndromes 4Hodgkin Disease 4Pituitary Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Lymphoma, T-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell 3Dendritic Cell Sarcoma, Interdigitating 3Breast Neoplasms 3Anemia, Refractory, with Excess of Blasts 3Rhabdoid Tumor 2Polycystic Ovary Syndrome 2Obesity 2Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Juvenile 2

Interventions

Etoposide 6Vincristine 5Prednisone 5Doxorubicin 5Cyclophosphamide 5Rituximab 4prednylidene 3deltacortene 3daratumumab 2Cytarabine 2varlilumab 1pomalidomide 1merphos 1ixazomib 1carmustine, poliferprosan 20 drug combination 1belantamab mafodotin 1Vorinostat 1Specimen Handling 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Hydrocortisone 1Disulfides 1Dexamethasone 1Carmustine 1CT-P10 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmablastic Lymphoma × Hydrocortisone × Clear all
NCT02481310 2022-02-21

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Northwestern University

Phase 1/2 Unknown
38 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡